胰激肽原酶治疗早期糖尿病肾病和临床糖尿病肾病的疗效比较被引量：13

Comparison of curative effects of kallidinogenase between patients with early diabetic nephropathy and patients with clinical diabetic nephropathy

下载PDF

导出

摘要目的:比较胰激肽原酶(怡开)治疗早期糖尿病肾病和临床糖尿病肾病的临床疗效。方法:根据尿白蛋白排泄率(UAER)水平将糖尿病患者分为早期糖尿病肾病组和临床糖尿病肾病组。两组患者均给予怡开40 U,1次/日,肌注8周。每周测定所有患者的UAER。结果:早期糖尿病肾病组患者治疗4周后UAER由治疗前的(182.5±85.6)mg/24 h减少到(112.6±35.4)mg/24 h(P<0.05),而且随治疗时间延长UAER减少愈明显,第6周已降至(55.4±25.4)mg/24 h(P<0.05)。临床糖尿病肾病组在治疗后第7周UAER由治疗前的(728.5±282.4)mg/24 h减少到(525.4±128.1)mg/24 h(P<0.05)。结论:胰激肽原酶能显著降低糖尿病肾病患者的UARE水平,对早期糖尿病肾病的疗效优于临床糖尿病肾病。 <Abstrat>In this paper,by means of the refined Cauchy's inequality,a inequality similar to Hilbert's inequality is improved.A new inequality is built:∞n=1∞m=1a_mb_nln　m+ln　n+1<π∞n=1na2_n∞n=1nb2_n1/2(1-R)1/2.where R=(α,γ)‖α‖-(β,γ)‖β‖2.

作者石琳琳张秀英刘波卢丹姚文华

机构地区吉林大学中日联谊医院内分泌科吉林大学基础医学院病理生物学教育部重点实验室

出处《吉林大学学报（医学版）》 CAS CSCD 北大核心 2005年第6期934-936,共3页 Journal of Jilin University：Medicine Edition

基金国家自然科学基金资助课题(30471767)

关键词胰激肽原酶糖尿病糖尿病肾病/药物疗法 Hardy-Hilbert's inequality Cauchy's inequality weight coefficient

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献9

1佟之复,李宁华,苗俊梅,张培兰.2型糖尿病肾病流行病学研究进展[J].中国老年学杂志,2001,21(3):241-242. 被引量：40
2Li LS. End-stage renal disease in China [J]. Kidney Int,1996, 49: 287-292.
3Tomow L, Cambien F, Rossing P, et al. Lack of relationship between an insertion/ deletion poly, orphism in the anglotensin I converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM Patients [J]. Diabetes,1995, 44: 489-494.
4Heesom AE, Hibberd ML. Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type 1 diabetes [J].Diabetes, 1997, 46 (2): 287-291.
5Morohid I, Mogyorosi A, Han DC, et al. Stimulation of TGF-βtype II receptor by high glucose in mousemessangial cells and in diabetic kidney [J]. Am J Physiol (Renal Physiol), 2000, 278: F830.
6Kang DH, Johnson RJ. Vascular endothelial growth factorza new player in the pathogenesls of renal fibrosis [J]. Curt Opln Nephrol Hypertens, 2002, 12 (1) : 43-49.
7赵雪梅,李才,张秀云,苗春生.糖肾安改善糖尿病大鼠肾脏病变的作用[J].吉林大学学报（医学版）,2005,31(1):31-34. 被引量：2
8Emanueli C, Madeddu P. Human tissue kallikrein: A new bullet for the treatment of ischemia [J]. Curr Pharm Design,2003, (9): 589-597.
9姚合斌,潘长玉,陆思珍,郭爱岩,汪寅章.激肽系统在实验性糖尿病肾病发展中的作用研究[J].中国糖尿病杂志,2000,8(6):356-359. 被引量：68

二级参考文献30

1孙林,易著文,虞佩兰.川芎嗪对人胎肾小球系膜细胞增殖的影响及其机理探讨[J].中国中西医结合杂志,1995,15(3):134-136. 被引量：95
2黄翠玲,李才,邓义斌,王丽娟,张秀云,赵丽艳.大黄对糖尿病大鼠肾组织非酶促糖基化的影响[J].中国糖尿病杂志,1996,4(2):103-106. 被引量：56
3[1]Bakris GL,Stein JH.Diabetic nephropathy[J].Dis Mon,1993;39(8):573-611
4[2]Brancati FL,Cusumano AM.Epidemiology and prevention of diabetic nephropathy[J].Curr Opin Nephrol Hypertens,1995;4(3):223-229
5[3]Breyer JA.Diabetic nephropathy in insulin-dependent patients[J].Am J Kindey Dis,1992;20:533-547
6[4]Hostetter TH.Early renal function in diabetes and risk factors for development of diabetic nephropathy.in:Jacobson HR,Striker CE,Klahr S,eds.The principles and practice of nephrology[M].Philadelphia BC Decker,1991:460-462
7[5]Mongensen CE.Microalbuminuria as a predictor of clinical diabetic nephropathy[J].Kidney Int,1987;31(2):673-689
8[6]Viberti GC,Wiseman M.The kidney in diabetes:Significance of early abnormalities[J].Clin Endocrinol Metab,1986;9:85-92
9[7]Nielsen S,Schmitz A,Mogensen CE.Rate of progression of nephropathy in normal and microalbuminurial type Ⅱ diabetic patients.Diabetologia[J],1991;34(suppl 2):A144
10[8]Schmitz A.Microalbuminuria and mortality in non-insulin-depen dent diabetes.In:Mogensen CE,ed.The Kidney and Hypertension in Diabetesc[M].Boston:Martinus Nijhoff Publishing,1988:6570